FDA Approves US Merck's Recarbrio for the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Ltd. or No Alternative Treatment Options Are Available

PureTech Acquires New Clinical-Stage Program LYT-100 to Treat Lymphedema

Sun Pharma Launches Access Program for Patients Prescribed Xelpros in the US

US FDA grants priority review status to Novartis' crizanlizumab

Sosei reports FDA approval for APP13007 IND for first-in-human (FIH) clinical trial in the US

Erchonia granted FDA approval of FX 635 for relief of chronic musculoskeletal pain

FDA approves Recarbrio for complicated urinary tract and complicated intra-abdominal infections

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3

Verm Publishes New Study Demonstrating Overa's Greater Sensitivity in Detecting Ovarian Cancer Compared with ROMA, HE4 + CA125, and CA125 Alone

Seattle Genetics and Astellas Submit Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

Q'Apel Medical wins US FDA clearance for Walrus Balloon Guide Catheter

US FDA grants breakthrough Therapy Designation to Dicerna Pharmaceuticals' DCR-PHXC

AstraZeneca's Imfinzi Granted orphan drug designation

Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1

Bayer wins US FDA approval for Gadato to assess myocardial perfusion and late gadolinium enhancement in adult patients with CAD